Recursion Pharmaceuticals Inc (RXRX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Recursion Pharmaceuticals Inc stock $0.67, price $3.52, that is 80.9% below the price, quality 23 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $2.84 – $28.83 · fair‑value band $0.4420 – $0.8330 · the $3.52 price screens above the $0.6715 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Recursion Pharmaceuticals in your weekly email
Every Wednesday you see whether Recursion Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Show moreShow less
The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Stock analysis
Recursion Pharmaceuticals Inc (RXRX) currently trades at $3.52, while our model-based Fair Value estimate is $0.6715, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.4420 (bear) to $0.8330 (bull), the price of $3.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Recursion Pharmaceuticals Inc reported revenue of $74.7M in FY2025 versus $10.0M in FY2021, a compound +65.3%/yr. Reported net income was −$645M in FY2025.
Key figures
Market cap $2.1B Mid · P/S ratio 41.7 · EPS (TTM) $−1.00 · Return on equity −56.6% · Return on assets (EBIT) −39.1% (5-year average) · Operating margin −1,760% · Revenue (TTM) $54.9M · Revenue growth (YoY) −60.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −81%, RXRX screens richer than that median.
Fair Value models
Bear$0.4420Fair Value $0.6715Bull$0.8330
Price $3.52 · Downside -80.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.5200$0.7900$0.980055
All 1 models by family
Asset-Based
NCAV (Graham)$0.5200$0.7900$0.980055
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, 5 officers or directors sold shares worth $1.4M and none bought.
SaleBlake BorgesonDirector12× since Dec 2, 2025: 1,110,000 shares, avg. $4.05$4.5MNov 3, 202610b5-1 plan
SaleRobert HershbergDirector25,000 shares at $5.00$125,000Oct 6, 202610b5-1 plan
SaleNajat KhanCEO and President, Director4× since Dec 22, 2025: 198,697 shares, avg. $4.06$806,737Sep 8, 202610b5-1 plan
SaleNamandje BumpusDirector2× since Jun 3, 2026: 8,349 shares, avg. $3.37$28,129Jun 18, 202610b5-1 plan
SaleChristopher GibsonDirector13× since Nov 19, 2025: 520,000 shares, avg. $3.82$2.0MJun 5, 202610b5-1 plan
SaleBen R TaylorChief Financial Officer3× since Dec 29, 2025: 42,765 shares, avg. $3.69$157,704Mar 17, 202610b5-1 plan
Plus 24 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+26.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+87.6%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,479.2% (2020) → −867.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: The AI platform's proven ability to generate partner-validated assets such as the Sanofi-optioned immunology candidate forms the main strength, while heavy losses, negative margins and repeated equity raises remain the central weakness.
Main risk: The need for repeated equity raises to fund operations through late-stage trials poses the biggest risk to the company's business model by threatening cash runway and increasing dilution.
Recursion's AI platform has delivered a first-in-class immunology candidate that Sanofi has now optioned for further development. Positive early data on REC-4881 in FAP add to the pipeline momentum, yet repeated equity raises remain necessary to fund operations through late-stage trials. Does the platform's ability to generate partner-validated assets outweigh the dilution that comes with extending the cash runway?
Compare Recursion Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−80.9% · Bottom 25%
Profitability
Return on assets−43.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−60.1% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.84× · Cheaper than median
P/S (12 months)37.87× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Recursion Pharmaceuticals Inc (RXRX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $0.6715 versus a price of $3.52, about 81% lower (overvalued).
What is the fair value of RXRX?
Our model-based fair value for Recursion Pharmaceuticals Inc is $0.6715 (as of Nov 6, 2026), built from audited fundamentals. The current price: $3.52.
What is the quality score of RXRX?
Recursion Pharmaceuticals Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Recursion Pharmaceuticals Inc (RXRX)?
Our model-based price target is the fair value of $0.6715 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $0.4420, optimistic scenario $0.8330. It is a calculation from audited fundamentals, not an analyst target.
What is the Recursion Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.6715, about 81% lower versus a price of $3.52 (overvalued). Cautious scenario $0.4420, optimistic scenario $0.8330. The calculation is refreshed regularly with new filings.
What is the revenue of Recursion Pharmaceuticals Inc (RXRX)?
Recursion Pharmaceuticals Inc reported trailing-twelve-month revenue of about $54.9M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Recursion Pharmaceuticals Inc (RXRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Recursion Pharmaceuticals Inc it is $0.6715 per share (as of Nov 6, 2026), against a price of $3.52. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Recursion Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, RXRX trades above its calculated fair value: price $3.52, fair value $0.6715, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RXRX?
No. The price is what the market pays today ($3.52); the fair value is what the company's own numbers justify ($0.6715). For Recursion Pharmaceuticals Inc the two are $2.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Recursion Pharmaceuticals Inc worth?
The market values Recursion Pharmaceuticals Inc at about $2.1B (market capitalisation, as of Nov 6, 2026). Per share that is $3.52; our models calculate a fair value of $0.6715 per share.
What do the bullish and bearish scenarios say about RXRX?
Our models span a range for Recursion Pharmaceuticals Inc: cautious scenario $0.4420, base $0.6715, optimistic $0.8330 per share (as of Nov 6, 2026, price $3.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Recursion Pharmaceuticals Inc (RXRX)?
Balance-sheet figures for Recursion Pharmaceuticals Inc (as of Nov 6, 2026): return on equity −56.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is RXRX from its 52-week high?
Recursion Pharmaceuticals Inc trades at $3.52, about 29% below its 52-week high of $4.96 and 24% above the low of $2.84 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6715 is for.
Which stocks are comparable to Recursion Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Recursion Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $3.52, calculated fair value $0.6715 (−81%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RXRX calculated?
We run Recursion Pharmaceuticals Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.6715 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Recursion Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Recursion Pharmaceuticals Inc (RXRX)?
The closing price on Nov 6, 2026 was $3.52. Our model-based fair value is $0.6715, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Recursion Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.8330). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4420 to $0.8330) leaves room in how you read the outcome.
Key figures of Recursion Pharmaceuticals Inc
How large is the market capitalisation of Recursion Pharmaceuticals Inc (RXRX)?
The market capitalisation of Recursion Pharmaceuticals Inc is $2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Recursion Pharmaceuticals Inc (RXRX)?
The price-to-sales ratio of Recursion Pharmaceuticals Inc is 41.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Recursion Pharmaceuticals Inc (RXRX)?
Earnings per share at Recursion Pharmaceuticals Inc are $−1.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Recursion Pharmaceuticals Inc (RXRX)?
The return on equity (ROE) of Recursion Pharmaceuticals Inc is −56.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Recursion Pharmaceuticals Inc (RXRX)?
On an EBIT basis the return on assets of Recursion Pharmaceuticals Inc is −39.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Recursion Pharmaceuticals Inc (RXRX)?
The operating margin of Recursion Pharmaceuticals Inc is −1,760% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Recursion Pharmaceuticals Inc (RXRX)?
Revenue at Recursion Pharmaceuticals Inc is growing −60.1% versus a year earlier (3y avg +23.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Recursion Pharmaceuticals Inc (RXRX) generate?
The free cash flow of Recursion Pharmaceuticals Inc is −$378M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Recursion Pharmaceuticals Inc (RXRX) hold?
Recursion Pharmaceuticals Inc holds more cash than debt, $665M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Recursion Pharmaceuticals Inc in the live analysis
One click puts Recursion Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
